Ianalumab Produces Encouraging Early Activity in Phase 1 Study of CLL
Kerry Rogers, MD, discusses the findings observed in the phase 1b study of ianalumab in combination with ibrutinib as treatment of patients with chronic lymphocytic leukemia on ibrutinib therapy.
Kerry Rogers, MD, hematologist/oncologist, assistant professor, Department of Hematology, The Ohio State University Comprehensive Cancer Center–James, discusses the findings observed in the phase 1b study of ianalumab (VAY736) in combination with ibrutinib (Imbruvica) as treatment of patients with chronic lymphocytic leukemia (CLL) on ibrutinib therapy.
This therapy was tolerable, which was not surprising as antibodies are generally tolerable, Rogers says. One surprising finding, however, was the number of patients that had elimination of their CLL and were able to stop treatment. Despite this being a phase 1 study, many patients were able to achieve this, according to Rogers. The study was not powered to detect this, but it was great to see that level of efficacy early on, Rogers says.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL
December 18th 2024During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Read More
